https://sputniknews.in/20251211/russia-plans-to-launch-its-cancer-vaccine-in-2026-10206899.html
Russia Plans to Launch Its Cancer Vaccine in 2026
Russia Plans to Launch Its Cancer Vaccine in 2026
Sputnik India
The first batches of the messenger RNA (mRNA)–based melanoma vaccine are already ready, Alexander Gintsburg, director of the Gamaleya Center for Epidemiology... 11.12.2025, Sputnik India
2025-12-11T21:11+0530
2025-12-11T21:11+0530
2025-12-11T21:11+0530
science & tech
science & tech
russia
health
moscow
https://cdn1.img.sputniknews.in/img/07e9/0c/04/10159572_0:320:3072:2048_1920x0_80_0_0_4d1804091ebeb098157dfb656322d3c3.jpg
Earlier, Russia’s Ministry of Health granted approval for the clinical use of the mRNA vaccine Neooncovac for melanoma therapy, developed by the same center.
https://sputniknews.in/20250922/made-in-russia-new-consumers-drive-economy-to-next-age-9804901.html
russia
moscow
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2025
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
News
en_IN
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
https://cdn1.img.sputniknews.in/img/07e9/0c/04/10159572_256:0:2987:2048_1920x0_80_0_0_5e92a2c4163d1fc9f5129d2cdae800be.jpgSputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
science & tech, russia, health, moscow
science & tech, russia, health, moscow
Russia Plans to Launch Its Cancer Vaccine in 2026
The first batches of the messenger RNA (mRNA)–based melanoma vaccine are already ready, Alexander Gintsburg, director of the Gamaleya Center for Epidemiology and Microbiology in Moscow told Sputnik.
"Three batches have been produced—not meant for human injection, but to test how the equipment works and to establish the necessary quality controls, confirming that the vaccine meets all verified parameters. This has been done. The vaccine that will be given to people will be produced in the new year," Gintsburg stated.
Earlier, Russia’s Ministry of Health granted approval for the clinical use of the mRNA vaccine Neooncovac for melanoma therapy, developed by the same center.